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Background and objectives: Vascular calcification and atherosclerosis have 
been related with an excess of cardiovascular mortality associated with 
chronic kidney disease (CKD). Different proteins such as osteoprotegerin 
(OPG), osteopontin (OPN) are involved in both conditions. In addition, soluble 
tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) is a 
proinflammatory cytokine that has been related to cardiovascular disease. We 
hypothesized that circulating levels of OPG, OPN and sTWEAK may relate to 
a higher prevalence of cardiovascular outcomes in patients with CKD. 
Design, setting, participants, & measurements: Baseline circulating levels 
of OPG, OPN and sTWEAK were measured in 565 patients with CKD stages 
3-5D [age, 61(48-68) years old, median (IQR); 359 men] without any previous 
CV event from The National Observatory of Atherosclerosis in Nephrology 
(NEFRONA) Study. Patients were followed for cardiovascular outcomes 
(follow-up of 3.11±1.26 years). 
Results: After the follow-up, 30 fatal and 33 nonfatal cardiovascular events 
occurred. At baseline, OPG and OPN levels were increased and sTWEAK 
concentrations were decreased in CKD patients suffering a fatal or nonfatal 
cardiovascular event. In a Cox model, after controlling for potential 
confounding factors, patients with OPG or OPN above and sTWEAK below 
optimal cut-off points obtained from ROC analysis had a higher risk of fatal 
and nonfatal cardiovascular events [HR: 2.62 (1.59-5.04); p<0.01; 2.88 (1.59-
5.24); p<0.005; 2.00 (1.04-3.84), p<0.05; respectively]. In addition, when CKD 
patients were grouped according to the number of biomarkers above (OPG 
and OPN) or below (sTWEAK) of their cut-off points, the combination of the 
three biomarkers had the highest risk for fatal and nonfatal cardiovascular 
events [HR: 10.25 (3.51-29.91); p<0.001]. 
Conclusions: Combination of OPG, OPN and sTWEAK impacted the 
predictability of cardiovascular outcomes. 
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Introduction 
Chronic kidney disease (CKD) is associated with a high incidence of 
cardiovascular events (CVE) and mortality (1). In fact, CVE and mortality 
increase progressively as glomerular filtration rate decreases (2-3). Traditional 
risk factors such as hyperlipidemia, hypertension, diabetes and smoking fail to 
fully explain the increased CV risk in CKD patients (4). Tools able to improve 
CV risk assessment are needed in CKD patients. In this context, the addition 
of vascular calcification (VC) scores to traditional risk factors improves CV risk 
assessment in CKD patients (5). 
Vascular calcification is the result of an accumulation of calcium and 
phosphate salts within the arterial wall as well as in cardiac valves. Data from 
animal models have identified different factors such as osteopontin (OPN) and 
osteoprotegerin (OPG) as factors that may regulate calcification in the arterial 
wall (6-7). OPG is a key cytokine that belongs to the tumor necrosis factor 
(TNF) receptor superfamily, which has a range of pleiotropic effects on bone 
metabolism, endocrine function and the immune system (8). OPG inhibits 
osteoclastic bone resorption by binding to the receptor activator of nuclear 
factor-κB ligand (RANKL), acting as a decoy receptor to competitively inhibit 
RANKL interaction with its receptor, RANK (9). Circulating OPG levels have 
been associated with the presence of VC and all-cause mortality in CKD 
patients (10). In addition, elevated serum OPG levels increased the risk of 
CVD and all-cause mortality in elderly women, and the association was more 
evident in women with poorer renal function (11). On the other hand, OPN 
belongs to the small integrin-binding ligand N-linked glycoprotein family (12). 
This protein is produced and secreted by different cell types such as 
macrophages, T cells, renal and vascular smooth muscle cells (VSMCs) as 
well as osteoblast and osteoclast (13). In CKD, elevated levels of OPN 
predicted overall and cardiovascular mortality, although this effect was lost 
after adjustment for inflammatory biomarkers (14). 
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a 
proinflammatory cytokine of the TNF-superfamily that circulates in serum as a 
soluble form (sTWEAK). Different studies have demonstrated a key role of 
this cytokine in atherosclerotic plaque development, progression and rupture 
(15-17). Recently, it has been demonstrated that TWEAK also participates in 
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VSMC calcification (18). In addition, loss-of function experiments have shown 
that TWEAK increases atherosclerotic plaque calcification (15). Finally, 
circulating soluble TWEAK (sTWEAK) levels have been associated with 
cardiovascular outcomes in CKD patients (19-20). 
The National Observatory of Atherosclerosis in Nephrology (NEFRONA) 
Study is a multicenter, observational, prospective study designed to analyze 
the prevalence of atherosclerosis and its associated risk factors in patients 
with CKD (21). In this study, we evaluated the association between selected 
calcification biomarkers, sTWEAK and their combination with cardiovascular 
outcomes in the NEFRONA population. 
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Material and Methods 
Study Population  
Participants included 565 CKD 3-5D patients from NEFRONA Study (21). 
Briefly, the study included male and female without history of CVD (acute 
myocardial infarction, angina pectoris, hemorrhagic or ischemic stroke, 
atherosclerosis, and abdominal aortic aneurysm). CKD patients in this sub-
study were enrolled within 57 Spanish primary care centers distributed in 32 
different regions from Spain. The exclusion criteria included previous CV 
events, pregnancy, having received any organ transplantation, active 
infections and, having a life expectancy of <1 year. 
Events 
Primary outcomes were CVD events according to the International 
Classification of Diseases of the World Health Organization, which included 
myocardial infarction, unstable angina, transient ischemic attack, 
cerebrovascular accident, arrhythmia, congestive heart failure, peripheral 
artery disease or amputation for vascular disease, and aorta aneurism. CV 
mortality was defined as cerebrovascular accident (ischemic or hemorrhagic), 
myocardial ischemia and infarction, hyperkalemia or arrhytmia, sudden death, 
hemorrhage due to aneurysm rupture and mesenteric infarct. Non-CV 
mortality causes included neoplasia, accident, infection, uremic, non-
determined or unknown. 
The local Ethics Committee of the Hospital Arnau de Vilanova approved the 
protocol. The authors adhere to the declaration of Helsinki and patients were 
included after providing informed consent. 
Clinical and biochemical data 
Patients were asked to complete a questionnaire at recruitment including 
clinical history of hypertension, dyslipidemia and diabetes, CV risk factors and 
medication use. Biochemical parameters were obtained from a routine fasting 
blood test. Serum sTWEAK levels was determined in duplicate with a 
commercially available ELISA kit (Bender MedSystems), and OPG and OPN 
levels by multiplex kits (Merck Millipore).  
 
Statistical Analysis 
Statistical analyses were performed using SPSS 11.0 (SPSS Inc, Chicago, IL) 
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statistical package. Normally distributed variables were expressed as 
mean±SD, and non-normally distributed variables were expressed as 
medians (IQR, expressed as the 25th and 75th percentile). Between-group 
comparisons were assessed for nominal variables with the chi-squared test 
and Mann-Whitney U test. Spearman rank correlation was used to determine 
correlations between variables. A receiver operator characteristic curve 
analysis was done to determine the OPG, OPN and sTWEAK cut-off points 
and maximum sensitivity and highest specificity for prediction of 
cardiovascular event. A categorical variable was generated containing the 
information of the number of biomarkers that were over (or under, in the case 
of sTWEAK) the cut-off point. Time to event analysis of CV outcomes was 
done using the Cox proportional hazards model, including adjustment for 
potential confounding factors. Data are presented in the form of Hazard ratios 
(HRs) and 95% confidence intervals (95% CIs). Statistical differences in c 
statistics were compared using the method by DeLong et al. (25); 95% CIs 
were calculated for each comparison. Kaplan-Meier curves were used to 
compare time to outcome according to a multimarker score. P value <0.05 




Characteristics of patient population according to cardiovascular outcomes 
are summarized in Table 1. Patients free for CV event included CKD stage III 
(N=157), stage 4-5 (N=152) or being in dialysis (N=193). Patients suffering a 
CV event included CKD stage III (N=10), stage 4-5 (N=16) or being in dialysis 
(N=37). The baseline levels of OPG, OPN and sTWEAK in the overall 
population were median (IQR): 119 (86-174) pg/mL, 109 (66-190) ng/mL and 
343 (214-514) pg/mL, respectively. 
There were significant differences among CKD patients suffering a CV event 
regarding age, SBP, glucose concentrations, eGFR, diabetes, and circulating 
OPG, OPN and sTWEAK levels (Table 1).  
Univariate association of OPG, OPN and sTWEAK are given in Table 2. The 
three biomarkers correlated with cholesterol and LDL-c concentrations, eGFR 
and ABI. In addition, OPG was positively correlated with OPN. OPG and OPN 
were negatively associated with sTWEAK. 
 
OPG, OPN, sTWEAK and CV outcomes 
Cardiovascular outcomes were determined from the day of examination 
onward, with a mean follow-up of 3.11±1.26 years. Sixty-two patients died; 30 
died from cardiovascular mortality (cancer [N=12], infection [N=16], and 
others [N=12]). Causes of cardiovascular disease were myocardial infarction 
(N=11), mesenteric infarction (N=7), sudden death (N=4), stroke (N=5), or 
other CV-related causes (N=3). OPG and OPN levels were higher in patients 
suffering a fatal CV event compared with those free for fatal CV event [OPG 
median (IQR): 212 (120-293) versus 118 (85-168) pg/mL; p<0.001; OPN 
median (IQR): 160 (112-231) versus 106 (112-231) ng/mL; p=0.002]. 
However In contrast, sTWEAK concentrations were lower in patients suffering 
a fatal CV event compared with those free for fatal CV event [median (IQR): 
211(139-367) versus 350 (221-517); p=0.01]. 
Because of the limited number of fatal CV events registered, we analyzed the 
effect of OPG, OPN and sTWEAK levels on the prediction of CV events for a 
composite of fatal and nonfatal CV events (N=63). During the follow up, 33 
additional nonfatal CV events were registered; unstable angina (N=8), 
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myocardial infarction (N=6), cerebrovascular accident (N=5); intermittent 
claudication (N=8), and other CV event (N=6). Characteristics of patient 
population according to cardiovascular outcomes are summarized in Table 1. 
There were significant differences among CKD patients suffering a CV event 
regarding age, SBP, glucose concentrations, eGFR, diabetes, and circulating 
OPG, OPN and sTWEAK levels. 
ROC curves were generated by logistic regression model to assess the 
prediction values of baseline OPG, OPN and sTWEAK levels (Fig. 1A). The 
ROC curve of patients with fatal and nonfatal CV events showed an area 
under the curve (AUC) of 0.69 (95%CI: 0.61-0.77; p<0.001) for OPG. A OPG 
threshold level >179 pg/mL had the highest combined sensitivity (56%) and 
specificity (81%) for the identification of individuals suffering a CV event. 
Similar AUC were found for OPN [AUC=0.63 (95% CI: 0.57-0.70); p<0.001] 
and sTWEAK [AUC=0.63 (95%CI: 0.56-0.69); p<0.001]. A OPN threshold 
level of >11.4 ng/mL and sTWEAK threshold concentration <307 pg/mL had 
the highest sensitivity (73% and 67%, respectively) and specificity (57% and 
58%, respectively) for the identification of patients suffering a CV event. 
Kaplan-Meier curves showed a significant association of OPG or OPN above 
and sTWEAK below cut-off points with probability to suffer a CV event 
(p<0.001 for all) (Fig. 1B). 
The predictors for time-to-cardiovascular event (N=63, including a composite 
of fatal and nonfatal) were studied by univariate and multivariate Cox analysis. 
In univariate Cox, age, diabetes, eGFR, being on dialysis, insulin treatment, 
OPG or OPN above and sTWEAK below of their cut-off points obtained from 
ROC analysis were significant predictors of outcome (Table 3). Multivariate 
Cox was used to study the effect of variables that were statistically significant 
in the univariate analysis. After that, only OPG or OPN above and sTWEAK 
below of their cut-off points persisted as independent predictors of CV events 
(Table 3).  
Since the three biomarkers correlate with each other and are independent 
predictors of CV events, a multimarker combination was developed according 
to the number of biomarkers whose values were above (OPG and OPN) or 
below (sTWEAK) of their cut-off points. Thus, a patient could have a 
multimarker score of 0 to 3. The score value was 0 in 31.2% patients, 1 in 
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34.5%, 2 in 23.0% and 3 in 11.3%. Kaplan-Meier curve showed a significant 
association of multimarker score with probability to suffer a CV event (Fig. 
2A). Using this score in the Cox proportional hazards model, score 2 or 3 
were significant predictors of outcome (Table 3). After adjustment by variables 
statistically significant in the univariate analysis, both score 2 or 3 persisted as 
independent predictors of CV events (Table 3). 
Finally, to assess the clinical usefulness of multimarker score in predicting CV 
outcomes in CKD patients, we created multivariable regression models with or 
without multimarker score. The model with conventional CV risk factors 
included age, sex, hyperlipidemia, hypertension, diabetes, and smoking status 
as well as eGFR. According to c statistics, the model including the 
multimarker score has shown a significant improvement from HR (95%CI): 
0.71 (0.65-0.78) to 0.79 (95%CI, 0.72-0.85) in accuracy of CV events 
prediction (p=0.013) (Fig. 2B). 
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Discussion 
In this work, we investigated OPG, OPN and sTWEAK serum levels as 
predictors of CV outcomes in CKD patients with or without CV risk factors but 
without any history of CVD. Specifically, we have observed that higher levels 
of calcification biomarkers OPG or OPN while lower levels of sTWEAK were 
associated with significantly greater risk of fatal and non-fatal CV events. In 
addition, we demonstrated that a combination of these biomarkers improves 
CV events prediction in CKD patients, being the first report showing the 
predictive value of this panel of biomarkers. 
It has been demonstrated that OPG is directly secreted from the 
vascular wall (22). OPG can modulate inflammation, apoptosis and calcium 
deposition in atherosclerotic plaques and cardiac valves (22). The beneficial 
role of OPG has been demonstrated in genetically modified mice. Thus, 
genetic deletion of osteoprotegerin in ApoE knockout mice accelerates 
advanced atherosclerotic lesion progression and calcification (23). In addition, 
osteoprotegerin injection in ApoE deficient mice promotes fibrous cap 
formation, contributing to plaque stabilization (24). In contrast, high levels of 
OPG have been associated with increased aortic and coronary calcification in 
patients (25), with vascular calcification in experimental models (CITA 
Panizo,..Valdivielso. Circ Res. 2009 104:1041-8) and with CV events in CKD 
patients (14, 26). Accordingly, we have demonstrated that OPG levels are 
negatively associated with eGFR and that high concentrations of OPG can 
predict CV events in the NEFRONA population. The discrepancy between the 
potential beneficial effects of OPG and their high levels observed in CKD 
patients could be explained by a compensatory mechanism to counteract 
vascular calcium deposition in the arterial wall of CKD patients. 
OPN is also expressed and secreted from the vascular wall and bone 
tissue, plays a role in atherosclerotic plaque development (27) and contributes 
to kidney damage in mice (28). Furthermore, OPN has been used as a marker 
of phenotypic transformation of VSMC in to osteoblast-like cells, (Lau Adv 
Chronic Kidney Dis. 2011 March ; 18(2): 105–112) and its expression is 
increased in human aortic valvular lesions (O'Brien KD, Osteopontin is 
expressed in human aortic valvular lesions. Circulation. 1995;92:2163–2168).  
However, its effects on vascular calcification are not clear. Thus, whereas 
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OPN levels increase in calcified aortas human (Chen et al Mol Cell Biochem. 
392(:65-76) and in experimental models of vitamin D toxicity and uremia 
(Moe, Kidney Int. 2003 63:1003-11), OPN is able to inhibit in vitro calcification, 
(Wada, Circ Res. 1999 84(:166-78) and OPN deficient cells show increased 
VC levels (Speer, Cardiovasc Res. 2005 66:324-33).  
In humans, OPN levels have been shown to be a good marker of the 
atherosclerotic process, reflecting not only atherosclerotic extension but also 
plaque susceptibility to rupture. In addition, treatments aimed to reduce 
atherosclerosis (statins, by pass, etc) also reduced OPN levels.(Wolak, 
Atherosclerosis. 2014 Oct;236(2):327-37) OPN concentrations have been 
associated with the prediction of total and cardiovascular mortality in CKD 
patients (14). However, this association was lost after adjustment for 
inflammatory markers. In the present paper, we observed that OPN negatively 
correlate with both eGFR and OPG and we demonstrated that OPN levels 
predict CV events in CKD patients, independently of inflammatory markers 
such as CRP or sTWEAK.  
sTWEAK is a proinflammatory cytokine that participates in the 
development, progression and rupture of atherosclerotic plaques (15-17). In 
addition, it has been recently reported and active role of TWEAK on vascular 
calcification. Thus, loss-of-function experiments have demonstrated that 
TWEAK diminished atherosclerotic plaque calcification (15). In addition, 
TWEAK favors phosphate-induced calcification in cultured VSMC (18). 
However, effects of TWEAK and OPG in vascular calcification should be 
independent since it has been demonstrated that TWEAK induces 
macrophage differentiation into osteoclasts in the presence of OPG, indicating 
a different mechanism of action (29). Confirming data of previous works (19-
20), we observed that sTWEAK levels are independently associated with CV 
events in CKD patients. 
The most important finding of our study is the association of a 
combination of biomarkers of vascular calcification (OPG and OPN) and 
inflammation (sTWEAK) with the risk of CV events. This combination showed 
a good discriminative power, suggesting that marker combinations integrating 
different biological mechanisms might better stratify CKD patients. Despite the 
independent association that we observed between multimarker score and 
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risk of fatal and non-fatal CV events, the inclusion of this multimarker score 
improves clinical risk prediction in our population. Our findings support the 
potential inclusion of these biomarkers in risk prediction algorithms. 
Finally, we want to highlight some limitations of our study for a correct 
interpretation of the results. Only CKD patients without history of CV events 
were included in the study. This was a necessary intentional bias because the 
study was aimed to primary prevention of CV events. A relative low number of 
fatal and non-fatal CV events was reported during the follow-up, which should 
limit the statistical power of our analysis. 
In conclusion, OPG, OPN and sTWEAK impacted the predictability of 
cardiovascular outcomes. The information provided by these biomarkers was 
additive because the risk of developing a CV event increased along with the 
number of them altered. Thus, a multimarker score including OPG, OPN and 
sTWEAK concentrations was independently and statistically associated with 
CV outcomes in CKD patients.  
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Figure Legends 
Figure 1.- Effect of OPN, OPG and sTWEAK on cardiovascular 
outcomes. 
A) Receiver-operating characteristic curves for cardiovascular prediction 
concerning OPG (red), OPN (green) or sTWEAK (blue) concentrations. 
B) Kaplan-Meier plot of event-free patients when patients were grouped 
according to OPG or OPN above and sTWEAK below of their optimal cut-off 
points. 
Figure 2.- Effect of multimarker score on cardiovascular outcomes. 
A) Kaplan-Meier plot of event-free patient for cardiovascular prediction 
according to multimarker score. 
B) Receiver-operating curves for cardiovascular events prediction. Curves are 
on the basis of logistic regression models incorporating conventional 
cardiovascular risk factors (age, sex, hyperlipidemia, hypertension, diabetes 
mellitus, smoking status, and eGFR) with or without multimarker score.  
 
Table 1.- Characteristics of CKD patients according to cardiovascular outcomes. 
 
 No (N=948) Yes (N=95) p 
Age, years 61 (50-68) 65 (58-70) <0.001 
Male, N (%) 588 (62) 69 (73) 0.02 
BMI, Kg/m2 28 (25-31) 28 (26-32) 0.39 
SBP, mmHg 140 (128-155) 149 (136-162) 0.001 
DBP, mmHg 80 (74-89) 81 (72-89) 0.96 
Cholesterol, mg/dL 177±39 180±50 0.61 
LDL-cholesterol, mg/dL 100±33 103±44 0.50 
HDL-cholesterol, mg/dL 47 (38-58) 43 (34-52) 0.02 
Triglycerides, mg/dL 126 (91-177) 138 (104-181) 0.17 
Glucose, mg/dL 98 (87-115) 117 (99-156) <0.001 
Hs-CRP, mg/L 1.83 (0.90-4.22) 3.25 (1.19-7.84) 0.006 
eGFR, mL/min/1.73 m2 26 (12-40) 21 (9.3-37) 0.08 
ABI 1.04 (0.96-1.15) 1.00 (0.88-1.18) 0.10 
c-IMT, mm 0.72 (0.61-0.87) 0.84 (0.68-1.15) <0.001 
Smoker, N (%) 532 (56) 61 (64) 0.08 
Dyslipemia, N (%) 






Diabetes Mellitus, N (%) 






Hypertension, N (%) 






Familial CVD, N (%) 78 (8) 11 (12) 0.18 
OPG, pg/mL 463 (254-672) 514 (278-992) 0.009 
OPN, ng/mL 20.4 (11.0-39.5) 24.1 (12.9-53.4) 0.043 
sTWEAK, pg/mL 399 (261-585) 293 (211-448) <0.001 
BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; eGFR: 
estimated glomerular filtration rate; hs-CRP: high-sensitivity C-reactive protein; ABI: Ankle-brachial index; c-IMT: carotid intima/media thickness. 
Table 2.- Spearman correlations coefficients between OPG, OPN, sTWEAK levels, and selected parameters in CKD patients. 
 
 
 OPG OPN sTWEAK 
 r p r p r p 
Age, years 0.15 <0.001 -0.05 0.12 -0.02 0.42 
BMI, kg/m2 -0.13 <0.001 -0.13 <0.001 0.03 0.27 
SBP, mm Hg 0.07 0.11 -0.02 0.95 0.03 0.25 
DBP, mm Hg -0.08 0.01 -0.01 0.85 -0.04 0.18 
Cholesterol, mg/dL -0.17 <0.001 -0.08 0.01 0.10 0.001 
HDL-c, mg/dL 0.01 0.72 0.01 0.69 0.11 0.001 
LDL-c, mg/dL -0.19 <0.001 -0.10 0.003 0.15 <0.001 
Triglicerydes, mg/dL -0.05 0.14 -0.02 0.53 -0.08 0.02 
Glucose, mg/dL -0.04 0.17 -0.13 <0.001 0.01 0.86 
Hs-CRP, mg/L 0.11 0.001 0.06 0.07 -0.04 0.22 
eGFR, mL/min/1.73m2 -0.48 <0.001 -0.42 <0.001 0.36 <0.001 
c-IMT, mm 0.16 <0.001 -0.04 0.25 -0.13 <0.001 
ABI 0.11 <0.001 0.08 0.01 -0.05 0.10 
OPG, pg/mL -------- -------- 0.48 <0.001 -0.22 <0.001 
OPN, ng/mL 0.48 <0.001 -------- -------- -0.11 0.001 
sTWEAK, pg/mL -0.22 <0.001 -0.11 0.001 -------- -------- 
 
 
BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-density lipoprotein; HDL: high-density lipoprotein; 
eGFR: estimated glomerular filtration rate; hs-CRP: high-sensitivity C-reactive protein; ABI: Ankle-brachial index; c-IMT: carotid intima/media 
thickness. 
Table 3.- Univariate and multivariate Cox regression analyses predicting cardiovascular outcomes. 
 
 




 Hazard Ratio 
CI (95%) 
p Hazard Ratio 
CI (95%) 
p Hazard Ratio 
CI (95%) 
p 
Age, per 10 years 1.34 (1.10-1.63) 0.004 1.24 (1.01-1.52) 0.04 1.25 (1.02-1.54) 0.03 
Gender, male vs female 1.61 (1.02-2.53) 0.04 1.77 (1.11-2.84) 0.02   1.95 (1.22-3.14)   0.005 
Current Smoker, yes vs no 1.39 (0.92-2.12) 0.12 --------------------- ---------   ---------------------   --------- 
Hypertension, yes vs no 1.45 (0.59-3.57) 0.42 --------------------- ---------   ---------------------   --------- 
Diabetes, yes vs no 2.83 (1.89-4.23) <0.001 2.05 (1.11-3.76) 0.02 2.02 (1.10-3.71) 0.02 
Hyperlipidemia, yes vs no 1.25 (0.79-1.96) 0.34 --------------------- ---------   ---------------------   --------- 
Familial CVD, yes vs no 1.43 (0.76-2.68) 0.27 --------------------- ---------   ---------------------   --------- 
eGFR, per 10 mL/min/1.73m2 0.79 (0.69-0.90) <0.001 0.97 (0.80-1.18) 0.79 0.92 (0.75-1.12) 0.39 
Dialysis, yes vs no 2.64 (1.70-4.08) <0.001 1.19 (0.58-2.46) 0.64 0.93 (0.42-2.09) 0.87 
Hs-CRP, >3 mg/L 1.84 (1.22-2.77) 0.003 1.45 (0.95-2.21) 0.08   1.39 (0.91-2.14)   0.13 
Antihypertensive drugs, yes vs no 0.98 (0.50-1.96) 0.97 --------------------- ---------   ---------------------   --------- 
Hypolipemic drugs, yes vs no 1.29 (0.85-1.97) 0.24 --------------------- ---------   ---------------------   --------- 
Oral antidiabetic drugs, yes vs no 1.01 (0.54-1.90) 0.96 --------------------- ---------   ---------------------   --------- 
Insulin treatment, yes vs no 2.82 (1.86-4.27) <0.001 1.33 (0.71-2.51) 0.37 1.40 (0.74-2.63) 0.30 
OPG > 869 pg/mL 3.98 (2.58-6.15) <0.001 1.96 (1.07-3.62) 0.03   ---------------------   --------- 
OPN > 35.5 ng/mL 2.02 (1.34-3.06) 0.001 1.69 (1.06-2.71) 0.03   ---------------------   --------- 
sTWEAK < 370 pg/mL 2.62 (1.71-4.01) <0.001 2.09 (1.30-3.34) 0.002   ---------------------   --------- 
0 Biomarkers 1.00 --------   1.00 -------- 
1 Biomarker 1.86 (1.10-3.15) 0.02 --------------------- --------- 1.44 (0.84-2.49) 0.19 
2 Biomarkers 1.95 (0.96-3.78) 0.07 --------------------- --------- 1.46 (0.65-3.30) 0.36 
3 Biomarkers 13.02 (7.16-23.69) <0.001 --------------------- --------- 9.95 (3.99-24.79) <0.001 
 
Multivariable Cox analysis included variables that were statistically significant in the univariate 
analysis. HR, Hazard ratio; 95% CI, 95% confidence interval; 
Model 1 adjusted also by OPG, OPN or sTWEAK based in their optimal cut-off points. 
Model 2 adjusted also by number of biomarkers above (OPG and OPN) or below (sTWEAK) of 
their optimal cut-off points.  
BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; LDL: low-
density lipoprotein; HDL: high-density lipoprotein; eGFR: estimated glomerular filtration rate; hs-
CRP: high-sensitivity C-reactive protein. 
 
 
Number at risk
Above cut-off point
Below cut-off point
893
150
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Below cut-off point
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